A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors

Inclusion criteria

• Able and willing to provide a written informed consent
• Subjects consented and willing to provide required tumor tissue of sufficient quantity and of adequate tumor tissue content
• Male or female
• Subjects with clinically or pathologically confirmed advanced (recurrent, unresectable or metastatic) solid tumors who have failed prior standard of care therapy
• ECOG performance status of 0-1

Exclusion criteria

• Has uncontrolled clinically symptomatic pleural effusion, pericardial effusion, carcinomatous ascites
• Has untreated brain metastasis, or with concomitant meningeal metastasis or spinal cord compression
• Has known history of other documented malignancy
• Has known history of acquired immunodeficiency syndrome (AIDS)
• Has significant cardiovascular disease that is not well controlled, such as: (1) New York Heart Association (NYHA) Grade ≥ 2 cardiac failure
• Has active or prior documented interstitial pneumonia/interstitial lung disease
• Has experienced Grade ≥ 2 hemorrhage events within 4 weeks prior to the first dose
• Has known active hepatitis B
• Has known allergies to SHR-1921 component
• Has other potential factors that may interfere with the study results, or result in the premature discontinuation as determined by the investigator.